{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:58:06Z","timestamp":1783490286174,"version":"3.55.0"},"reference-count":37,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2018,11,30]]},"DOI":"10.1536\/ihj.18-119","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T18:40:28Z","timestamp":1540406428000},"page":"1368-1377","source":"Crossref","is-referenced-by-count":28,"title":["Effects of Tolvaptan on Volume Overload in Patients with Heart Failure"],"prefix":"10.1536","volume":"59","author":[{"given":"Koichiro","family":"Kinugawa","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[{"name":"Internal Medicine, Cardiology and Intensive Care Unit, Nippon Medical School Musashi-Kosugi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","unstructured":"1. Ministry of Health, Labour and Welfare. Internet. In: Patient Survey in Fiscal; 2014 (Classification of diseases edition). Accessed February 2, 2018. Available at: http:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/kanja\/10syoubyo\/."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sato N, Kajimoto K, Keida T, <i>et al<\/i>. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 2013; 77: 944-51.","DOI":"10.1253\/circj.CJ-13-0187"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ambrosy AP, Pang PS, Khan S, <i>et al<\/i>. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 2013; 34: 835-43.","DOI":"10.1093\/eurheartj\/ehs444"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Peacock WF, Costanzo MR, De Marco T, <i>et al<\/i>. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009; 113: 12-9.","DOI":"10.1159\/000164149"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ahmed A, Husain A, Love TE, <i>et al<\/i>. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006; 27: 1431-9.","DOI":"10.1093\/eurheartj\/ehi890"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Miura M, Sugimura K, Sakata Y, <i>et al<\/i>. Prognostic impact of loop diuretics in patients with chronic heart failure- effects of addition of renin-angiotensin-aldosterone system inhibitors and \u03b2-blockers. Circ J 2016; 80: 1396-403.","DOI":"10.1253\/circj.CJ-16-0216"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J 2012; 33: 2135-42.","DOI":"10.1093\/eurheartj\/ehs205"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamamura Y, Nakamura S, Itoh S, <i>et al<\/i>. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-7.","DOI":"10.1016\/S0022-3565(24)37873-5"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Costello-Boerrigter LC, Smith WB, Boerrigter G, <i>et al<\/i>. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273-8.","DOI":"10.1152\/ajprenal.00195.2005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Xiong B, Huang Y, Tan J, <i>et al<\/i>. The short-term and long-term effects of tolvaptan in patients with heart failure: meta-analysis of randomized controlled trials. Heart Fail Rev 2015; 20: 633-42.","DOI":"10.1007\/s10741-015-9503-x"},{"key":"11","unstructured":"11. Yang CJ, Yang J, Yang J, Fan ZX. Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015; 8: 22117-28. eCollection 2015."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Alskaf E, Tridente A, Al-Mohammad A. Tolvaptan for heart failure, Systematic Review and Meta-Analysis of Trials. J Cardiovasc Pharmacol 2016; 68: 196-203.","DOI":"10.1097\/FJC.0000000000000405"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wang C, Xiong B, Cai L. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2017; 17: 164.","DOI":"10.1186\/s12872-017-0598-y"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Huang WL, Yang Y, Yang J, <i>et al<\/i>. Use of tolvaptan vs. furosemide in older patients with heart failure: Meta-analysis of randomized controlled trials. Herz 2018; 43: 338-45.","DOI":"10.1007\/s00059-017-4563-4"},{"key":"15","unstructured":"15. The Cochrane training. Data collection forms for intervention reviews, version 3; updated 2014. Accessed February 2, 2018. Available at: training.cochrane.org\/resource\/data-collection-forms-intervention-reviews"},{"key":"16","unstructured":"16. Higgins JP, Altman DG, Sterne JA, eds. Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Green S, eds. <i>Cochrane Handbook for Systematic Reviews of Interventions<\/i> Version 5.1.0; updated 2011. <i>The Cochrane Collaboration, 2011<\/i>. Accessed February 6, 2018. Available at: http:\/\/www.handbook.cochrane.org."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Higgins JP, Altman DG, G\u00f8tzsche PC, <i>et al<\/i>. The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.","DOI":"10.1136\/bmj.d5928"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Gheorghiade M, Niazi I, Ouyang J, <i>et al<\/i>. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107: 2690-6.","DOI":"10.1161\/01.CIR.0000070422.41439.04"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Gheorghiade M, Gattis WA, O&apos;Connor CM, <i>et al<\/i>. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.","DOI":"10.1001\/jama.291.16.1963"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Gheorghiade M, Konstam MA, Burnett JC Jr, <i>et al<\/i>. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-43.","DOI":"10.1001\/jama.297.12.1332"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T, Tolvaptan Investigators. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther 2011; 25: S19-31.","DOI":"10.1007\/s10557-011-6303-y"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25: S33-45.","DOI":"10.1007\/s10557-011-6304-x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Udelson JE, Bilsker M, Hauptman PJ, <i>et al<\/i>. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail 2011; 17: 973-81.","DOI":"10.1016\/j.cardfail.2011.08.005"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Jujo K, Saito K, Ishida I, <i>et al<\/i>. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 2016; 3: 177-88.","DOI":"10.1002\/ehf2.12088"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Kimura K, Momose T, Hasegawa T, <i>et al<\/i>. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 2016; 67: 399-405.","DOI":"10.1016\/j.jjcc.2015.09.020"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Matsue Y, Suzuki M, Torii S, <i>et al<\/i>. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 2016; 22: 423-32.","DOI":"10.1016\/j.cardfail.2016.02.007"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Matsuyama K, Koizumi N, Nishibe T, <i>et al<\/i>. Effects of short-term administration of tolvaptan after open heart surgery. Int J Cardiol 2016; 220: 192-5.","DOI":"10.1016\/j.ijcard.2016.06.156"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Felker GM, Mentz RJ, Cole RT, <i>et al<\/i>. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017; 69: 1399-406.","DOI":"10.1016\/j.jacc.2016.09.004"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Konstam MA, Kiernan M, Chandler A, <i>et al<\/i>. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 2017; 69: 1409-19.","DOI":"10.1016\/j.jacc.2016.12.035"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Tamaki S, Sato Y, Yamada T, <i>et al<\/i>. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction - prospective randomized controlled study. Circ J 2017; 81: 740-7.","DOI":"10.1253\/circj.CJ-16-1122"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Inomata T, Ikeda Y, Kida K, <i>et al<\/i>. Effects of Additive Tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment- Results from the K-STAR Study. Circ J 2017; 82: 159-67.","DOI":"10.1253\/circj.CJ-17-0179"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kinugawa K, Inomata T, Sato N, <i>et al<\/i>. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study). Int Heart J 2015; 56: 137-43.","DOI":"10.1536\/ihj.14-332"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kida K, Shibagaki Y, Tominaga N, <i>et al<\/i>. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study. Clin Pharmacokinet 2015; 54: 273-84.","DOI":"10.1007\/s40262-014-0194-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Imamura T, Kinugawa K, Fujino T, <i>et al<\/i>. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240-9.","DOI":"10.1253\/circj.CJ-14-0244"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Imamura T, Kinugawa K. Mid-term administration of tolvaptan improves renal function accompanied by dose-reduction in furosemide in aquaporin-defined responders. Int Heart J 2015; 56: 686-7.","DOI":"10.1536\/ihj.15-298"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Matsue Y, Ter Maaten JM, Suzuki M, <i>et al<\/i>. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clin Res Cardiol 2017; 106: 802-12.","DOI":"10.1007\/s00392-017-1122-1"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Shoaf SE, Kim SR, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects. Eur J Clin Pharmacol 2012; 68: 1595-603.","DOI":"10.1007\/s00228-012-1295-5"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/6\/59_18-119\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:35:19Z","timestamp":1775252119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/6\/59_18-119\/_article"}},"subtitle":["Meta-Analysis of Randomized Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.18-119","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}